{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:02:23Z","timestamp":1794405743324,"version":"4.9.0"},"reference-count":128,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>This review investigates the efficacy of deutetrabenazine in the management of chorea\nrelated to HD. Motor, psychological, and cognitive symptoms characterize HD, a neurodegenerative\ndisease. One prominent movement disorder associated with HD is chorea, which results in uncontrollably\njerky movements of the muscles. HD has no known cure; instead, symptom management\nwith a variety of medication options is the main goal. Effective management is essential because\nchorea has a significant impact on patients' quality of life. Dutetrabenazine is the first deuterated\nmedication to receive approval from the US Food and Drug Administration (FDA) for the\ntherapeutic treatment of chorea in Huntington's disease (HD). Treating chorea associated with HD\nmay benefit from the use of deutetrabenazine. The novel compound deutetrabenazine contains deuterium.\nIt inhibits CYP2D6 metabolism, prolongs the half-lives of active metabolites, and may\ncause persistent systemic exposure while maintaining significant pharmacological action. Deutetrabenazine\ndecreases the release of monoamines, including dopamine, in the synaptic cleft by inhibiting\nthe VMAT2 vesicular monoamine transporter. For chorea, this mechanism has a therapeutic\neffect. For the treatment of choreiform movement and tardive dyskinesia in HD, the FDA approved\ndeutetrabenazine in 2017. Here we highlight, Deutetrabenazine as a promising new treatment\nfor Huntington's disease chorea, for patients with chorea, deutetrabenazine offers hope for an\nenhanced quality of life. To completely understand its effectiveness and potential advantages, additional\nresearch is necessary, including direct comparison studies, as a result of the mixed study results.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0127724328312991241001051813","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T01:23:59Z","timestamp":1729473839000},"page":"269-288","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease"],"prefix":"10.2174","volume":"20","author":[{"given":"Siddhant","family":"Tripathi","sequence":"first","affiliation":[{"name":"Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune, Maharashtra, 411038, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashika","family":"Sharma","sequence":"additional","affiliation":[{"name":"Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune, Maharashtra, 411038, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department\nof Pharma Chemistry, Manipal College of Pharmaceutical Sciences, Manipal, Karnataka, 576104, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"MacDonald M.","year":"1993","unstructured":"MacDonald M.; A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell  1993,72(6),971-983","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/mds.25996","volume":"29","author":"Jankovic J.","year":"2014","unstructured":"Jankovic J.; Roos R.A.C.; Chorea associated with Huntington\u2019s disease: To treat or not to treat? Mov Disord  2014,29(11),1414-1418","journal-title":"Mov Disord"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"Coppen E.M.","year":"2017","unstructured":"Coppen E.M.; Roos R.A.C.; Current pharmacological approaches to reduce Chorea in Huntington\u2019s Disease. Drugs  2017,77(1),29-46","journal-title":"Drugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"Walker F.O.","year":"2007","unstructured":"Walker F.O.; Huntington\u2019s disease. Lancet  2007,369(9557),218-228","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","volume":"77","author":"Heo Y.A.","year":"2017","unstructured":"Heo Y.A.; Scott L.J.; Deutetrabenazine: A review in chorea associated with Huntington\u2019s Disease. Drugs  2017,77(17),1857-1864","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"McColgan P.","year":"2018","unstructured":"McColgan P.; Tabrizi S.J.; Huntington\u2019s disease: A clinical review. Eur J Neurol  2018,25(1),24-34","journal-title":"Eur J Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","year":"2006","unstructured":"Tetrabenazine as antichorea therapy in Huntington disease. Neurology Huntington Study Group 2006,66(3),366-372","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"tre-03-161-4138-1","DOI":"10.5334\/tohm.165","volume":"3","author":"Waln O.","year":"2013","unstructured":"Waln O.; Jankovic J.; An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y)  2013,3,tre-03-161-4138-1","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"Jankovic J.","year":"2016","unstructured":"Jankovic J.; Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother  2016,17(18),2461-2470","journal-title":"Expert Opin Pharmacother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.36469\/9779","volume":"6","author":"Sung V.W.","year":"2018","unstructured":"Sung V.W.; Gandhi S.K.; Abler V.; Davis B.; Irwin D.E.; Anderson K.E.; Iyer R.G.; Retrospective analysis of healthcare resource use, treatment patterns, and treatment-related events in patients with huntington\u2019s disease\u2013associated chorea initiated on tetrabenazine. J Health Econ Outcomes Res  2018,6(1),15-24","journal-title":"J Health Econ Outcomes Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"Reilmann R.","year":"2013","unstructured":"Reilmann R.; Pharmacological treatment of chorea in Huntington\u2019s disease\u2013good clinical practice versus evidence-based guideline. Mov Disord  2013,28(8),1030-1033","journal-title":"Mov Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamaneurol.2016.3916","volume":"73","author":"Reilmann R.","year":"2016","unstructured":"Reilmann R.; Deutetrabenazine\u2014not a revolution but welcome evolution for treating chorea in huntington disease. JAMA Neurol  2016,73(12),1404-1406","journal-title":"JAMA Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"Frank S.","year":"2016","unstructured":"Frank S.; Testa C.M.; Stamler D.; Kayson E.; Davis C.; Edmondson M.C.; Kinel S.; Leavitt B.; Oakes D.; O\u2019Neill C.; Vaughan C.; Goldstein J.; Herzog M.; Snively V.; Whaley J.; Wong C.; Suter G.; Jankovic J.; Jimenez-Shahed J.; Hunter C.; Claassen D.O.; Roman O.C.; Sung V.; Smith J.; Janicki S.; Clouse R.; Saint-Hilaire M.; Hohler A.; Turpin D.; James R.C.; Rodriguez R.; Rizer K.; Anderson K.E.; Heller H.; Carlson A.; Criswell S.; Racette B.A.; Revilla F.J.; Nucifora F.; Margolis R.L.; Ong M.; Mendis T.; Mendis N.; Singer C.; Quesada M.; Paulsen J.S.; Brashers-Krug T.; Miller A.; Kerr J.; Dubinsky R.M.; Gray C.; Factor S.A.; Sperin E.; Molho E.; Eglow M.; Evans S.; Kumar R.; Reeves C.; Samii A.; Chouinard S.; Beland M.; Scott B.L.; Hickey P.T.; Esmail S.; Fung W.L.A.; Gibbons C.; Qi L.; Colcher A.; Hackmyer C.; McGarry A.; Klos K.; Gudesblatt M.; Fafard L.; Graffitti L.; Schneider D.P.; Dhall R.; Wojcieszek J.M.; LaFaver K.; Duker A.; Neefus E.; Wilson-Perez H.; Shprecher D.; Wall P.; Blindauer K.A.; Wheeler L.; Boyd J.T.; Houston E.; Farbman E.S.; Agarwal P.; Eberly S.W.; Watts A.; Tariot P.N.; Feigin A.; Evans S.; Beck C.; Orme C.; Edicola J.; Christopher E.; Effect of deutetrabenazine on chorea among patients with huntington disease. JAMA  2016,316(1),40-50","journal-title":"JAMA"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","volume":"34","author":"Chen J.J.","year":"2012","unstructured":"Chen J.J.; Ondo W.G.; Dashtipour K.; Swope D.M.; Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin Ther  2012,34(7),1487-1504","journal-title":"Clin Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mds.21222","volume":"22","author":"Kenney C.","year":"2007","unstructured":"Kenney C.; Hunter C.; Jankovic J.; Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord  2007,22(2),193-197","journal-title":"Mov Disord"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2016.8011","volume":"316","author":"Geschwind M.D.","year":"2016","unstructured":"Geschwind M.D.; Paras N.; Deutetrabenazine for treatment of chorea in huntington disease. JAMA  2016,316(1),33-35","journal-title":"JAMA"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/JHD-2012-120009","volume":"1","author":"Galvan L.","year":"2012","unstructured":"Galvan L.; Andr\u00e9 V.M.; Wang E.A.; Cepeda C.; Levine M.S.; Functional differences between direct and indirect striatal output pathways in Huntington\u2019s Disease. J Huntingtons Dis  2012,1(1),17-25","journal-title":"J Huntingtons Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/ana.410270403","volume":"27","author":"Albin R.L.","year":"1990","unstructured":"Albin R.L.; Reiner A.; Anderson K.D.; Penney J.B.; Young A.B.; Striatal and nigral neuron subpopulations in rigid Huntington\u2019s disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol  1990,27(4),357-365","journal-title":"Ann Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-71779-1_1","volume":"1049","author":"Ghosh R.","year":"2018","unstructured":"Ghosh R.; Tabrizi S.J.; Clinical features of Huntington\u2019s Disease. Adv Exp Med Biol  2018,1049,1-28","journal-title":"Adv Exp Med Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/ene.13349","volume":"24","author":"Van de Zande N.A.","year":"2017","unstructured":"Van de Zande N.A.; Massey T.H.; McLauchlan D.; Pryce Roberts A.; Zutt R.; Wardle M.; Payne G.C.; Clenaghan C.; Tijssen M.A.J.; Rosser A.E.; Peall K.J.; Clinical characterization of dystonia in adult patients with Huntington\u2019s disease. Eur J Neurol  2017,24(9),1140-1147","journal-title":"Eur J Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1034\/j.1399-0004.2000.580108.x","volume":"58","author":"Squitieri F.","year":"2000","unstructured":"Squitieri F.; Berardelli A.; Nargi E.; Castellotti B.; Mariotti C.; Cannella M.; Luisa Lavitrano M.; De Grazia U.; Gellera C.; Ruggieri S.; Atypical movement disorders in the early stages of Huntington\u2019s disease: Clinical and genetic analysis. Clin Genet  2000,58(1),50-56","journal-title":"Clin Genet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jnnp.65.4.577","volume":"65","author":"Racette B.A.","year":"1998","unstructured":"Racette B.A.; Perlmutter J.S.; Levodopa responsive parkinsonism in an adult with Huntington\u2019s disease. J Neurol Neurosurg Psychiatry  1998,65(4),577-579","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/mds.870090609","volume":"9","author":"Thompson P.D.","year":"1994","unstructured":"Thompson P.D.; Bhatia K.P.; Brown P.; Davis M.B.; Pires M.; Quinn N.P.; Luthert P.; Honovar M.; O\u2019Brien M.D.; Marsden C.D.; Harding A.E.; Cortical myoclonus in huntington\u2019s disease. Mov Disord  1994,9(6),633-641","journal-title":"Mov Disord"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12883-017-0923-1","volume":"17","author":"Cui S.S.","year":"2017","unstructured":"Cui S.S.; Ren R.J.; Wang Y.; Wang G.; Chen S.D.; Tics as an initial manifestation of juvenile Huntington\u2019s disease: Case report and literature review. BMC Neurol  2017,17(1),152","journal-title":"BMC Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/09602011.2018.1564675","volume":"30","author":"Sherman C.W.","year":"2020","unstructured":"Sherman C.W.; Iyer R.; Abler V.; Antonelli A.; Carlozzi N.E.; Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians. Neuropsychol Rehabil  2020,30(6),1150-1168","journal-title":"Neuropsychol Rehabil"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40271-018-0312-x","volume":"11","author":"Thorley E.M.","year":"2018","unstructured":"Thorley E.M.; Iyer R.G.; Wicks P.; Curran C.; Gandhi S.K.; Abler V.; Anderson K.E.; Carlozzi N.E.; Understanding how chorea affects health-related quality of life in huntington disease: An Online survey of patients and caregivers in the United States. Patient  2018,11(5),547-559","journal-title":"Patient"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3233\/JHD-140109","volume":"3","author":"Sitek E.J.","year":"2014","unstructured":"Sitek E.J.; Thompson J.C.; Craufurd D.; Snowden J.S.; Unawareness of deficits in Huntington\u2019s disease. J Huntingtons Dis  2014,3(2),125-135","journal-title":"J Huntingtons Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3233\/JHD-200410","volume":"9","author":"Isaacs D.","year":"2020","unstructured":"Isaacs D.; Gibson J.S.; Stovall J.; Claassen D.O.; The impact of anosognosia on clinical and patient-reported assessments of psychiatric symptoms in Huntington\u2019s disease. J Huntingtons Dis  2020,9(3),291-302","journal-title":"J Huntingtons Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JHD-160228","volume":"5","author":"Simpson J.A.","year":"2016","unstructured":"Simpson J.A.; Lovecky D.; Kogan J.; Vetter L.A.; Yohrling G.J.; Survey of the Huntington\u2019s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis  2016,5(4),395-403","journal-title":"J Huntingtons Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","year":"1996","unstructured":"Unified Huntington\u2019s disease rating scale: Reliability and consistency. Mov Disord Huntington Study Group 1996,11(2),136-142","journal-title":"Mov Disord"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mds.870050202","volume":"5","author":"Penney J.B.","year":"1990","unstructured":"Penney J.B.; Young A.B.; Shoulson I.; Starosta-Rubenstein S.; Snodgrass S.R.; Sanchez-Ramos J.; Ramos-Arroyo M.; Gomez F.; Penchaszadeh G.; Alvir J.; Esteves J.; DeQuiroz I.; Marsol N.; Moreno H.; Conneally P.M.; Bonilla E.; Wexler N.S.; Huntington\u2019s disease in venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord  1990,5(2),93-99","journal-title":"Mov Disord"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/mds.23816","volume":"26","author":"Reilmann R.","year":"2011","unstructured":"Reilmann R.; Bohlen S.; Kirsten F.; Ringelstein E.B.; Lange H.W.; Assessment of involuntary choreatic movements in Huntington\u2019s disease\u2014Toward objective and quantitative measures. Mov Disord  2011,26(12),2267-2273","journal-title":"Mov Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mds.870130120","volume":"13","author":"Boo G.D.","year":"1998","unstructured":"Boo G.D.; Tibben A.; Hermans J.; Maat A.; Roos R.A.C.; Subtle involuntary movements are not reliable indicators of incipient Huntington\u2019s disease. Mov Disord  1998,13(1),96-99","journal-title":"Mov Disord"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mdc3.12571","volume":"5","author":"Mestre T.A.","year":"2018","unstructured":"Mestre T.A.; Forjaz M.J.; Mahlknecht P.; Cardoso F.; Ferreira J.J.; Reilmann R.; Sampaio C.; Goetz C.G.; Cubo E.; Martinez-Martin P.; Stebbins G.T.; Rating scales for motor symptoms and signs in Huntington\u2019s disease: Critique and recommendations. Mov Disord Clin Pract (Hoboken)  2018,5(2),111-117","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuropsychologia.2015.10.033","volume":"79","author":"Johnson E. B.","year":"2015","unstructured":"Johnson E. B.; Rees E. M.; Labuschagne I.; Durr A.; Leavitt B. R.; Roos R. A.; Reilmann R.; Johnson H.; Hobbs N. Z.; Langbehn D. R.; Stout J. C.; Tabrizi S. J.; Scahill R. I.; The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia  2015,79(Pt A),138-46","journal-title":"Neuropsychologia"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"Tabrizi S.J.","year":"2012","unstructured":"Tabrizi S.J.; Reilmann R.; Roos R.A.C.; Durr A.; Leavitt B.; Owen G.; Jones R.; Johnson H.; Craufurd D.; Hicks S.L.; Kennard C.; Landwehrmeyer B.; Stout J.C.; Borowsky B.; Scahill R.I.; Frost C.; Langbehn D.R.; Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol  2012,11(1),42-53","journal-title":"Lancet Neurol"},{"key":"ref=37","author":"Rosenblatt A.","year":"1999","unstructured":"Rosenblatt A.; Ranen G.; Nance M.; Paulsen J.;  A physician's guide to the management of Huntington disease  1999","journal-title":"A physician's guide to the management of Huntington disease"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11910-010-0163-x","volume":"11","author":"Goodman A.O.G.","year":"2011","unstructured":"Goodman A.O.G.; Rogers L.; Pilsworth S.; McAllister C.J.; Shneerson J.M.; Morton A.J.; Barker R.A.; Asymptomatic sleep abnormalities are a common early feature in patients with Huntington\u2019s disease. Curr Neurol Neurosci Rep  2011,11(2),211-217","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archneur.1991.00530140106023","volume":"48","author":"Fish D.R.","year":"1991","unstructured":"Fish D.R.; Sawyers D.; Allen P.J.; Blackie J.D.; Lees A.J.; Marsden C.D.; The effect of sleep on the dyskinetic movements of Parkinson\u2019s disease, Gilles De la Tourette syndrome, Huntington\u2019s disease, and torsion dystonia. Arch Neurol  1991,48(2),210-214","journal-title":"Arch Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00415-005-0709-z","volume":"252","author":"Hurelbrink C.B.","year":"2005","unstructured":"Hurelbrink C.B.; Lewis S.J.G.; Barker R.A.; The use of the Actiwatch\u2013Neurologica system to objectively assess the involuntary movements and sleep\u2013wake activity in patients with mild\u2013moderate Huntington\u2019s disease. J Neurol  2005,252(6),642-647","journal-title":"J Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/mdc3.12258","volume":"3","author":"Ranjan S.","year":"2016","unstructured":"Ranjan S.; Kohler S.; Harrison M.B.; Quigg M.; Nocturnal post-arousal chorea and repetitive ballistic movement in Huntington\u2019s disease. Mov Disord Clin Pract (Hoboken)  2016,3(2),200-202","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JHD-160197","volume":"5","author":"Andrzejewski K.L.","year":"2016","unstructured":"Andrzejewski K.L.; Dowling A.V.; Stamler D.; Felong T.J.; Harris D.A.; Wong C.; Cai H.; Reilmann R.; Little M.A.; Gwin J.T.; Biglan K.M.; Dorsey E.R.; Wearable sensors in Huntington Disease: A pilot study. J Huntingtons Dis  2016,5(2),199-206","journal-title":"J Huntingtons Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000502136","volume":"3","author":"Gordon M.F.","year":"2019","unstructured":"Gordon M.F.; Grachev I.D.; Mazeh I.; Dolan Y.; Reilmann R.; Loupe P.S.; Fine S.; Navon-Perry L.; Gross N.; Papapetropoulos S.; Savola J.M.; Hayden M.R.; Quantification of motor function in huntington disease patients using wearable sensor devices. Digit Biomark  2019,3(3),103-115","journal-title":"Digit Biomark"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000479018","volume":"1","author":"Adams J.L.","year":"2017","unstructured":"Adams J.L.; Dinesh K.; Xiong M.; Tarolli C.G.; Sharma S.; Sheth N.; Aranyosi A.J.; Zhu W.; Goldenthal S.; Biglan K.M.; Dorsey E.R.; Sharma G.; Multiple wearable sensors in parkinson and huntington disease individuals: A pilot study in clinic and at home. Digit Biomark  2017,1(1),52-63","journal-title":"Digit Biomark"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","volume":"84","author":"Evans S.J.W.","year":"2013","unstructured":"Evans S.J.W.; Douglas I.; Rawlins M.D.; Wexler N.S.; Tabrizi S.J.; Smeeth L.; Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry  2013,84(10),1156-1160","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"Fisher E.R.","year":"2014","unstructured":"Fisher E.R.; Hayden M.R.; Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk. Mov Disord  2014,29(1),105-114","journal-title":"Mov Disord"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-801893-4.00001-8","volume":"144","author":"Nance M.A.","year":"2017","unstructured":"Nance M.A.; Genetics of Huntington disease. Handb Clin Neurol  2017,144,3-14","journal-title":"Handb Clin Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","volume":"330","author":"Kremer B.","year":"1994","unstructured":"Kremer B.; Goldberg P.; Andrew S.E.; Theilmann J.; Telenius H.; Zeisler J.; Squitieri F.; Lin B.; Bassett A.; Almqvist E.; Bird T.D.; Hayden M.R.; A worldwide study of the Huntington\u2019s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med  1994,330(20),1401-1406","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S0100-879X2003000200002","volume":"36","author":"Newsholme P.","year":"2003","unstructured":"Newsholme P.; Lima M.M.R.; Procopio J.; Pithon-Curi T.C.; Doi S.Q.; Bazotte R.B.; Curi R.; Glutamine and glutamate as vital metabolites. Braz J Med Biol Res  2003,36(2),153-163","journal-title":"Braz J Med Biol Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"DiFiglia M.","year":"1997","unstructured":"DiFiglia M.; Sapp E.; Chase K.O.; Davies S.W.; Bates G.P.; Vonsattel J.P.; Aronin N.; Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science  1997,277(5334),1990-1993","journal-title":"Science"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1006\/nbdi.1998.0168","volume":"4","author":"Becher M.W.","year":"1998","unstructured":"Becher M.W.; Kotzuk J.A.; Sharp A.H.; Davies S.W.; Bates G.P.; Price D.L.; Ross C.A.; Intranuclear neuronal inclusions in Huntington\u2019s disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis  1998,4(6),387-397","journal-title":"Neurobiol Dis"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.spen.2006.11.006","author":"Lutz R.E.","year":"2007","unstructured":"Lutz R.E.;  Seminars in pediatric neurology  2007,26-33","journal-title":"Seminars in pediatric neurology"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2016.06.033","volume":"91","author":"Tremblay R.","year":"2016","unstructured":"Tremblay R.; Lee S.; Rudy B.; GABAergic interneurons in the neocortex: From cellular properties to circuits. Neuron  2016,91(2),260-292","journal-title":"Neuron"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","volume":"13","author":"Alexander G.E.","year":"1990","unstructured":"Alexander G.E.; Crutcher M.D.; Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci  1990,13(7),266-271","journal-title":"Trends Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0168-0102(02)00027-5","volume":"43","author":"Nambu A.","year":"2002","unstructured":"Nambu A.; Tokuno H.; Takada M.; Functional significance of the cortico\u2013subthalamo\u2013pallidal \u2018hyperdirect\u2019 pathway. Neurosci Res  2002,43(2),111-117","journal-title":"Neurosci Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neuron.2016.09.007","volume":"92","author":"Straub C.","year":"2016","unstructured":"Straub C.; Saulnier J.L.; B\u00e8gue A.; Feng D.D.; Huang K.W.; Sabatini B.L.; Principles of synaptic organization of GABAergic interneurons in the striatum. Neuron  2016,92(1),84-92","journal-title":"Neuron"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1073858418807887","volume":"25","author":"Plotkin J.L.","year":"2019","unstructured":"Plotkin J.L.; Goldberg J.A.; Thinking outside the box (and arrow): Current themes in striatal dysfunction in movement disorders. Neuroscientist  2019,25(4),359-379","journal-title":"Neuroscientist"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","volume":"198","author":"Raymond L.A.","year":"2011","unstructured":"Raymond L.A.; Andr\u00e9 V.M.; Cepeda C.; Gladding C.M.; Milnerwood A.J.; Levine M.S.; Pathophysiology of Huntington\u2019s disease: Time-dependent alterations in synaptic and receptor function. Neuroscience  2011,198,252-273","journal-title":"Neuroscience"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","volume":"17","author":"Wyant K.J.","year":"2017","unstructured":"Wyant K.J.; Ridder A.J.; Dayalu P.; Huntington\u2019s disease\u2014update on treatments. Curr Neurol Neurosci Rep  2017,17(4),33","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3182885eb3","volume":"80","author":"Suchowersky O.","year":"2013","unstructured":"Suchowersky O.; Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American academy of neurology. Neurology  2013,80(10),970","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737175.2018.1500178","volume":"18","author":"Bashir H.","year":"2018","unstructured":"Bashir H.; Jankovic J.; Deutetrabenazine for the treatment of Huntington\u2019s chorea. Expert Rev Neurother  2018,18(8),625-631","journal-title":"Expert Rev Neurother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"Armstrong M.J.","year":"2012","unstructured":"Armstrong M.J.; Miyasaki J.M.;  Neurology Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology 2012,79(6),597-603","journal-title":"Neurology"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","volume":"76","author":"Vijayakumar D.","year":"2016","unstructured":"Vijayakumar D.; Jankovic J.; Drug-induced dyskinesia, part 1: Treatment of levodopa-induced dyskinesia. Drugs  2016,76(7),759-777","journal-title":"Drugs"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1212\/WNL.59.5.694","volume":"59","author":"Verhagen Metman L.","year":"2002","unstructured":"Verhagen Metman L.; Morris M.J.; Farmer C.; Gillespie M.; Mosby K.; Wuu J.; Chase T.N.; Huntington\u2019s disease. Neurology  2002,59(5),694-699","journal-title":"Neurology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","volume":"14","author":"Rosas H.D.","year":"1999","unstructured":"Rosas H.D.; Koroshetz W.J.; Jenkins B.G.; Chen Y.I.; Hayden D.L.; Beal M.F.; Cudkowicz M.E.; Riluzole therapy in Huntington\u2019s disease (HD). Mov Disord  1999,14(2),326-330","journal-title":"Mov Disord"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s004150170071","volume":"248","author":"Seppi K.","year":"2001","unstructured":"Seppi K.; Mueller J.; Bodner T.; Brandauer E.; Benke T.; Weirich-Schwaiger H.; Poewe W.; Wenning G.K.; Riluzole in Huntington\u2019s disease (HD): An open label study with one year follow up. J Neurol  2001,248(10),866-869","journal-title":"J Neurol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"CD001359","DOI":"10.1002\/14651858.CD001359.pub2","volume":"18","author":"Duggan L.","year":"2005","unstructured":"Duggan L.; Fenton M.; Rathbone J.; Dardennes R.; El-Dosoky A.; Indran S.; Olanzapine for schizophrenia. Cochrane Database Syst Rev  2005,18(2),CD001359","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=68","first-page":"69","volume":"14","author":"Squitieri F.","year":"2001","unstructured":"Squitieri F.; Cannella M.; Porcellini A.; Brusa L.; Simonelli M.; Ruggieri S.; Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol  2001,14(1),69-72","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","volume":"53","author":"Fulton B.","year":"1997","unstructured":"Fulton B.; Goa K.L.; Olanzapine. Drugs  1997,53(2),281-298","journal-title":"Drugs"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1176\/appi.ps.52.7.967","volume":"52","author":"Ball M.P.","year":"2001","unstructured":"Ball M.P.; Coons V.B.; Buchanan R.W.; A program for treating olanzapine-related weight gain. Psychiatr Serv  2001,52(7),967-969","journal-title":"Psychiatr Serv"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","volume":"244","author":"Janssen P.A.","year":"1988","unstructured":"Janssen P.A.; Niemegeers C.J.; Awouters F.; Schellekens K.H.; Megens A.A.; Meert T.F.; Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther  1988,244(2),685-693","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"Duff K.","year":"2008","unstructured":"Duff K.; Beglinger L.J.; O\u2019Rourke M.E.; Nopoulos P.; Paulson H.L.; Paulsen J.S.; Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry  2008,20(1),1-3","journal-title":"Ann Clin Psychiatry"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","volume":"158","author":"Conley R.R.","year":"2001","unstructured":"Conley R.R.; Mahmoud R.; A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry  2001,158(5),765-774","journal-title":"Am J Psychiatry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"Timmins G.S.","year":"2014","unstructured":"Timmins G.S.; Deuterated drugs: Where are we now? Expert Opin Ther Pat  2014,24(10),1067-1075","journal-title":"Expert Opin Ther Pat"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e13030","DOI":"10.1111\/ijcp.13030","volume":"71","author":"Citrome L.","year":"2017","unstructured":"Citrome L.; Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract  2017,71(11),e13030","journal-title":"Int J Clin Pract"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"Frank S.","year":"2014","unstructured":"Frank S.; Treatment of Huntington\u2019s disease. Neurotherapeutics  2014,11(1),153-160","journal-title":"Neurotherapeutics"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1021\/acs.chemrev.1c00795","volume":"122","author":"Kopf S.","year":"2022","unstructured":"Kopf S.; Bourriquen F.; Li W.; Neumann H.; Junge K.; Beller M.; Recent developments for the deuterium and tritium labeling of organic molecules. Chem Rev  2022,122(6),6634-6718","journal-title":"Chem Rev"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","volume":"62","author":"Pirali T.","year":"2019","unstructured":"Pirali T.; Serafini M.; Cargnin S.; Genazzani A.A.; Applications of deuterium in medicinal chemistry. J Med Chem  2019,62(11),5276-5297","journal-title":"J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1021\/acs.joc.9b02552","volume":"85","author":"Looker A.R.","year":"2020","unstructured":"Looker A.R.; Wilde N.; Ryan M.P.; Roeper S.; Ye Z.; Lewandowski B.L.; Utilizing o -quinone methide chemistry: Synthesis of d  -ivacaftor. J Org Chem  2020,85(2),501-507","journal-title":"J Org Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1021\/acs.oprd.1c00468","volume":"26","author":"Treitler D.S.","year":"2022","unstructured":"Treitler D.S.; Soumeillant M.C.; Simmons E.M.; Lin D.; Inankur B.; Rogers A.J.; Dummeldinger M.; Kolotuchin S.; Chan C.; Li J.; Freitag A.; Lora Gonzalez F.; Smith M.J.; Sfouggatakis C.; Wang J.; Benkovics T.; Deerberg J.; Simpson J.H.; Chen K.; Tymonko S.; Development of a commercial process for deucravacitinib, a deuterated API for TYK2 inhibition. Org Process Res Dev  2022,26(4),1202-1222","journal-title":"Org Process Res Dev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1002\/anie.200700039","volume":"46","author":"Atzrodt J.","year":"2007","unstructured":"Atzrodt J.; Derdau V.; Fey T.; Zimmermann J.; The renaissance of H\/D exchange. Angew Chem Int Ed  2007,46(41),7744-7765","journal-title":"Angew Chem Int Ed"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1002\/anie.201708903","volume":"57","author":"Atzrodt J.","year":"2018","unstructured":"Atzrodt J.; Derdau V.; Kerr W.J.; Reid M.; C\u2212 H functionalisation for hydrogen isotope exchange. Angew Chem Int Ed  2018,57(12),3022-3047","journal-title":"Angew Chem Int Ed"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1039\/D0CS01496F","volume":"51","author":"Prakash G.","year":"2022","unstructured":"Prakash G.; Paul N.; Oliver G.A.; Werz D.B.; Maiti D.; C\u2013H deuteration of organic compounds and potential drug candidates. Chem Soc Rev  2022,51(8),3123-3163","journal-title":"Chem Soc Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41467-020-15310-z","volume":"11","author":"Rowbotham J.S.","year":"2020","unstructured":"Rowbotham J.S.; Ramirez M.A.; Lenz O.; Reeve H.A.; Vincent K.A.; Bringing biocatalytic deuteration into the toolbox of asymmetric isotopic labelling techniques. Nat Commun  2020,11(1),1454","journal-title":"Nat Commun"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.aap9674","volume":"358","author":"Loh Y.Y.","year":"2017","unstructured":"Loh Y.Y.; Nagao K.; Hoover A.J.; Hesk D.; Rivera N.R.; Colletti S.L.; Davies I.W.; MacMillan D.W.C.; Photoredox-catalyzed deuteration and tritiation of pharmaceutical compounds. Science  2017,358(6367),1182-1187","journal-title":"Science"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1039\/D0QO01299H","volume":"8","author":"Zhou R.","year":"2021","unstructured":"Zhou R.; Ma L.; Yang X.; Cao J.; Recent advances in visible-light photocatalytic deuteration reactions. Org Chem Front  2021,8(3),426-444","journal-title":"Org Chem Front"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1038\/s41467-022-32238-8","volume":"13","author":"Shi Q.","year":"2022","unstructured":"Shi Q.; Xu M.; Chang R.; Ramanathan D.; Pe\u00f1in B.; Funes-Ardoiz I.; Ye J.; Visible-light mediated catalytic asymmetric radical deuteration at non-benzylic positions. Nat Commun  2022,13(1),4453","journal-title":"Nat Commun"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1039\/D2CC00344A","volume":"58","author":"Norcott P.L.","year":"2022","unstructured":"Norcott P.L.; Current electrochemical approaches to selective deuteration. Chem Commun (Camb)  2022,58(18),2944-2953","journal-title":"Chem Commun (Camb)"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1039\/D1CS00907A","volume":"51","author":"Li N.","year":"2022","unstructured":"Li N.; Li Y.; Wu X.; Zhu C.; Xie J.; Radical deuteration. Chem Soc Rev  2022,51(15),6291-6306","journal-title":"Chem Soc Rev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"18645","DOI":"10.1002\/anie.202104254","volume":"60","author":"Wang L.","year":"2021","unstructured":"Wang L.; Xia Y.; Derdau V.; Studer A.; Remote site-selective radical C(sp)\u2212H monodeuteration of amides using DO. Angew Chem Int Ed  2021,60(34),18645-18650","journal-title":"Angew Chem Int Ed"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.1002\/chem.202101179","volume":"27","author":"Steverlynck J.","year":"2021","unstructured":"Steverlynck J.; Sitdikov R.; Rueping M.; The deuterated \u201cMagic Methyl\u201d group: A guide to site-selective trideuteromethyl incorporation and labeling by using CD reagents. Chemistry  2021,27(46),11751-11772","journal-title":"Chemistry"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"10806","DOI":"10.1039\/D1CS00544H","volume":"50","author":"Sun Q.","year":"2021","unstructured":"Sun Q.; Soul\u00e9 J.F.; Broadening of horizons in the synthesis of CD -labeled molecules. Chem Soc Rev  2021,50(19),10806-10835","journal-title":"Chem Soc Rev"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/nmt-2018-0042","volume":"9","author":"Niemann N.","year":"2019","unstructured":"Niemann N.; Jimenez-Shahed J.; Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag  2019,9(2),59-71","journal-title":"Neurodegener Dis Manag"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1021\/acs.oprd.8b00011","volume":"22","author":"Ray P.C.","year":"2018","unstructured":"Ray P.C.; Pawar Y.D.; Singare D.T.; Deshpande T.N.; Singh G.P.; Novel process for preparation of tetrabenazine and deutetrabenazine. Org Process Res Dev  2018,22(4),520-526","journal-title":"Org Process Res Dev"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nbt0617-493","volume":"35","author":"Schmidt C.","year":"2017","unstructured":"Schmidt C.; First deuterated drug approved. Nat Biotechnol  2017,35(6),493-494","journal-title":"Nat Biotechnol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd2784","volume":"8","author":"Hayden M.R.","year":"2009","unstructured":"Hayden M.R.; Leavitt B.R.; Yasothan U.; Kirkpatrick P.; Tetrabenazine. Nat Rev Drug Discov  2009,8(1),17-18","journal-title":"Nat Rev Drug Discov"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1021\/jm4007998","volume":"57","author":"Gant T.G.","year":"2014","unstructured":"Gant T.G.; Using deuterium in drug discovery: Leaving the label in the drug. J Med Chem  2014,57(9),3595-3611","journal-title":"J Med Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.133.3446.102","volume":"133","author":"Belleau B.","year":"1961","unstructured":"Belleau B.; Burba J.; Pindell M.; Reiffenstein J.; Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science  1961,133(3446),102-104","journal-title":"Science"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1111\/bcp.13702","volume":"84","author":"Schneider F.","year":"2018","unstructured":"Schneider F.; Erisson L.; Beygi H.; Bradbury M.; Cohen-Barak O.; Grachev I.D.; Guzy S.; Loupe P.S.; Levi M.; McDonald M.; Savola J.M.; Papapetropoulos S.; Tracewell W.G.; Velinova M.; Spiegelstein O.; Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)\/carbidopa compared to L-DOPA\/carbidopa following single oral dose administration in healthy subjects. Br J Clin Pharmacol  2018,84(10),2422-2432","journal-title":"Br J Clin Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd.2016.63","volume":"15","author":"Mullard A.","year":"2016","unstructured":"Mullard A.; Deuterated drugs draw heavier backing. Nat Rev Drug Discov  2016,15(4),219-221","journal-title":"Nat Rev Drug Discov"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1060028018797110","volume":"53","author":"Russak E.M.","year":"2019","unstructured":"Russak E.M.; Bednarczyk E.M.; Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Ann Pharmacother  2019,53(2),211-216","journal-title":"Ann Pharmacother"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/13543776.2017.1378350","volume":"27","author":"Timmins G.S.","year":"2017","unstructured":"Timmins G.S.; Deuterated drugs; updates and obviousness analysis. Expert Opin Ther Pat  2017,27(12),1353-1361","journal-title":"Expert Opin Ther Pat"},{"key":"ref=103","year":"2021","unstructured":"Novel Drug Approvals for 2021. FDA Available From:  https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-20212021"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S1092852918001219","volume":"23","author":"Stahl S.M.","year":"2018","unstructured":"Stahl S.M.; Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: Does one have advantages over the other? CNS Spectr  2018,23(4),239-247","journal-title":"CNS Spectr"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"Fernandez H.H.","year":"2017","unstructured":"Fernandez H.H.; Factor S.A.; Hauser R.A.; Jimenez-Shahed J.; Ondo W.G.; Jarskog L.F.; Meltzer H.Y.; Woods S.W.; Bega D.; LeDoux M.S.; Shprecher D.R.; Davis C.; Davis M.D.; Stamler D.; Anderson K.E.; Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology  2017,88(21),2003-2010","journal-title":"Neurology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1017\/S109285291800024X","volume":"23","author":"Cox D.S.","year":"2018","unstructured":"Cox D.S.; Levi M.; Rabinovich-Guilatt L.; Truong D.; Stamler D.; 127 cardiovascular safety assessment of deutetrabenazine in healthy volunteers and implications for patients with huntington disease or tardive dyskinesia. CNS Spectr  2018,23(1),80","journal-title":"CNS Spectr"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1124\/jpet.116.239160","volume":"361","author":"Grigoriadis D.E.","year":"2017","unstructured":"Grigoriadis D.E.; Smith E.; Hoare S.R.J.; Madan A.; Bozigian H.; Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther  2017,361(3),454-461","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/cts.12754","volume":"13","author":"Schneider F.","year":"2020","unstructured":"Schneider F.; Bradbury M.; Baillie T.A.; Stamler D.; Hellriegel E.; Cox D.S.; Loupe P.S.; Savola J.M.; Rabinovich-Guilatt L.; Pharmacokinetic and metabolic profile of deutetrabenazine (TEV-50717) compared with tetrabenazine in healthy volunteers. Clin Transl Sci  2020,13(4),707-717","journal-title":"Clin Transl Sci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/acs.biochem.7b00765","volume":"57","author":"DeWitt S.H.","year":"2018","unstructured":"DeWitt S.H.; Maryanoff B.E.; Deuterated drug molecules: Focus on FDA-approved deutetrabenazine. Biochemistry  2018,57(5),472-473","journal-title":"Biochemistry"},{"key":"ref=110","year":"2017","unstructured":"Highlights of prescribing information. Teva Pharmaceuticals 2017"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"P1.054","DOI":"10.1212\/WNL.86.16_supplement.P1.054","volume":"86","author":"Stamler D.","year":"2016","unstructured":"Stamler D.; Bradbury M.; De Boer L.; Offman E.; A relative bioavailability study of three dose strengths and four dose levels of SD-809, a potential treatment for movement disorders (P1.054). Neurology  2016,86,P1.054","journal-title":"Neurology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/cpdd.882","volume":"10","author":"Schneider F.","year":"2021","unstructured":"Schneider F.; Stamler D.; Bradbury M.; Loupe P.S.; Hellriegel E.; Cox D.S.; Savola J.M.; Gordon M.F.; Rabinovich-Guilatt L.; Pharmacokinetics of deutetrabenazine and tetrabenazine: Dose proportionality and food effect. Clin Pharmacol Drug Dev  2021,10(6),647-659","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=113","year":"2017","unstructured":"AUSTEDO (deutetrabenazine): US prescribing information. Teva. Pharmaceuticals USA Inc. Available From:   https:\/\/www.austedo.com\/globalassets\/austedo\/prescribing-information.pdf2017"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/nmt-2018-0040","volume":"9","author":"Richard A.","year":"2019","unstructured":"Richard A.; Frank S.; Deutetrabenazine in the treatment of Huntington\u2019s disease. Neurodegener Dis Manag  2019,9(1),31-37","journal-title":"Neurodegener Dis Manag"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"Frank S.","year":"2017","unstructured":"Frank S.; Stamler D.; Kayson E.; Claassen D.O.; Colcher A.; Davis C.; Duker A.; Eberly S.; Elmer L.; Furr-Stimming E.; Gudesblatt M.; Hunter C.; Jankovic J.; Kostyk S.K.; Kumar R.; Loy C.; Mallonee W.; Oakes D.; Scott B.L.; Sung V.; Goldstein J.; Vaughan C.; Testa C.M.; Safety of converting from tetrabenazine to deutetrabenazine for the treatment of Chorea. JAMA Neurol  2017,74(8),977-982","journal-title":"JAMA Neurol"},{"key":"ref=116","year":"2017","unstructured":"ClinicalTrials.gov is a place to learn about clinical studies from around the world. US National Institutes of Health Available From:     https:\/\/clinicaltrials.gov\/2017"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"Frank S.","year":"2022","unstructured":"Frank S.; Testa C.; Edmondson M.C.; Goldstein J.; Kayson E.; Leavitt B.R.; Oakes D.; O\u2019Neill C.; Vaughan C.; Whaley J.; Gross N.; Gordon M.F.; Savola J.M.; Frank S.; Testa C.; Stamler D.; Kayson E.; Edmondson M.C.; Leavitt B.R.; Oakes D.; O\u2019Neill C.; Vaughan C.; Goldstein J.; Bockus M.; Leyva S.; Snively V.; Whaley J.; Wong C.; Mallonee W.M.; Suter G.; Jankovic J.; Jimenez-Shahed J.; Hunter C.; Claassen D.O.; West L.; Roman O.; Sung V.; Smith J.; Clouse R.; Saint-Hilaire M.; Turpin D.; James R.; Rodriguez R.; Rizer K.; Anderson K.; Heller H.; Ahmad A.; Criswell S.; Racette B.A.; Nucifora F.C.; Churchill G.; Ong M.J.; Mendis T.; Mendis N.; Singer C.; Paulsen J.S.; Kerr J.; Dubinsky R.; Gray C.; Factor S.A.; Sperin E.; Molho E.; Evans S.; Nickels B.; Bergen C.; Jaynes J.; Reeves C.; Segro V.; Samii A.; Christopher E.; Del Castillo D.; Chouinard S.; Perry-Trice P.; Esmail S.; Fung W.L.A.; Gibbons C.; Colcher A.; Hackmyer C.; McGarry A.; Klos K.; Gudesblatt M.; Schneider D.; Dhall R.; Simpson E.; Wojcieszek J.; Hurt A.; LaFaver K.; Robinson A.; Revilla F.J.; Duker A.P.; Neefus E.; Wilson-Perez H.; Shprecher D.; Hohnholt T.; Wall P.; Boyd J.; Houston E.; Farbman E.S.; Poynor S.; Agarwal P.; Leon J.; Eberly S.; Watts A.; Tariot P.; Feigin A.; Evans S.R.; Beck C.A.; The safety of deutetrabenazine for chorea in huntington disease: An open-label extension study. CNS Drugs  2022,36(11),1207-1216","journal-title":"CNS Drugs"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","volume":"14","author":"Carroll J.B.","year":"2015","unstructured":"Carroll J.B.; Bates G.P.; Steffan J.; Saft C.; Tabrizi S.J.; Treating the whole body in Huntington\u2019s disease. Lancet Neurol  2015,14(11),1135-1142","journal-title":"Lancet Neurol"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.CON.0000436155.46909.c3","volume":"19","author":"Walker R.H.","year":"2013","unstructured":"Walker R.H.; Chorea. Continuum (Minneap Minn)  2013,19(5 Movement Disorders),1242-63","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"Anderson K.E.","year":"2017","unstructured":"Anderson K.E.; Stamler D.; Davis M.D.; Factor S.A.; Hauser R.A.; Isoj\u00e4rvi J.; Jarskog L.F.; Jimenez-Shahed J.; Kumar R.; McEvoy J.P.; Ochudlo S.; Ondo W.G.; Fernandez H.H.; Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry  2017,4(8),595-604","journal-title":"Lancet Psychiatry"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/jcph.2336","volume":"64","author":"Curtis K.","year":"2024","unstructured":"Curtis K.; Sung V.; Real-world experience with deutetrabenazine for huntington disease chorea. J Clin Pharmacol  2024,64(2),178-181","journal-title":"J Clin Pharmacol"},{"key":"ref=122","first-page":"P07.210","volume":"80","author":"Stamler D.","year":"2013","unstructured":"Stamler D.; Bradbury M.; Brown F.; The pharmacokinetics and safety of deuterated-tetrabenazine (P07.210). Neurol J  2013,80(7_supplement),P07.210","journal-title":"Neurol J"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/mdc3.12483","volume":"4","author":"Rodrigues F.B.","year":"2017","unstructured":"Rodrigues F.B.; Duarte G.S.; Costa J.; Ferreira J.J.; Wild E.J.; Tetrabenazine versus deutetrabenazine for huntington\u2019s disease: Twins or distant cousins? Mov Disord Clin Pract (Hoboken)  2017,4(4),582-585","journal-title":"Mov Disord Clin Pract (Hoboken)"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","volume":"4","author":"Claassen D.O.","year":"2017","unstructured":"Claassen D.O.; Carroll B.; De Boer L.M.; Wu E.; Ayyagari R.; Gandhi S.; Stamler D.; Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord  2017,4(1),3","journal-title":"J Clin Mov Disord"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/ijms25020864","volume":"25","author":"Battaglia S.","year":"2024","unstructured":"Battaglia S.; Di Fazio C.; Mazz\u00e0 M.; Tamietto M.; Avenanti A.; Targeting human glucocorticoid receptors in fear learning: A multiscale integrated approach to study functional connectivity. Int J Mol Sci  2024,25(2),864","journal-title":"Int J Mol Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/cells13100790","volume":"13","author":"Tanaka M.","year":"2024","unstructured":"Tanaka M.; Battaglia S.; Gim\u00e9nez-Llort L.; Chen C.; Hepsomali P.; Avenanti A.; V\u00e9csei L.; Innovation at the intersection: Emerging translational research in neurology and psychiatry. Cells  2024,13(10),790","journal-title":"Cells"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/antiox13060651","volume":"13","author":"Pagotto G.L.O.","year":"2024","unstructured":"Pagotto G.L.O.; Santos L.M.O.; Osman N.; Lamas C.B.; Laurindo L.F.; Pomini K.T.; Guissoni L.M.; Lima E.P.; Goulart R.A.; Catharin V.M.C.S.; Direito R.; Tanaka M.; Barbalho S.M.; Ginkgo biloba: A leaf of hope in the fight against alzheimer\u2019s Dementia: Clinical trial systematic review. Antioxidants  2024,13(6),651","journal-title":"Antioxidants"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.3390\/ijms21249338","volume":"21","author":"T\u00f6r\u00f6k N.","year":"2020","unstructured":"T\u00f6r\u00f6k N.; Tanaka M.; V\u00e9csei L.; Searching for peripheral biomarkers in neurodegenerative diseases: The tryptophan-kynurenine metabolic pathway. Int J Mol Sci  2020,21(24),9338","journal-title":"Int J Mol Sci"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328312991241001051813","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235285\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328312991241001051813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:34:13Z","timestamp":1756362853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235285\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328312991241001051813","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}